Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALPL | P05186 | 1/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | ALPG | P10696 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | PLEC | Q15149 | 1/20 | 0.57 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 15/20 | 0.53 |
| ▸ | CA1 | P00915 | 13/20 | 0.53 |
| ▸ | CA2 | P00918 | 13/20 | 0.53 |
| ▸ | CA12 | O43570 | 5/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14640188 | 0.92 | USP2 (0.74) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL12900563 | 0.91 | USP2 (0.72) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL20254033 | 0.86 | USP2 (0.77) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL10098714 | 0.85 | USP2 (0.76) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL12045940 | 0.84 | USP2 (0.68) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL25829608 | 0.83 | USP2 (0.80) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL14621716 | 0.82 | USP2 (0.66) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL1437042 | 0.81 | USP2 (0.78) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL173061 | 0.81 | USP2 (0.73) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL20248670 | 0.81 | USP2 (0.70) | USP2L3MBTL1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-06-12 | — | — | US | disclosed |
| US-7282575-B2 | Functional peptide nucleic acid monomer and process for producing the same | CREDIA JAPAN CO., LTD. (JP) | 2007-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | NSUN3, RNGTT, NSUN2 | USP2 2830/4885L3MBTL1 2666/4885MEN1 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.